Who Paid My Doc
Reditrex
Drug Rheumatology
NDC 66220-820-22
General payments
$149,980
Research payments
$0
Through program year 2023, $149,980 in general payments and $0 in research payments were reported against Reditrex (Rheumatology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | General | $2,009 | 49 |
| 2022 | General | $15,450 | 501 |
| 2021 | General | $132,404 | 246 |
| 2020 | General | $117 | 6 |
Breakdown
The top 5 of 45 recipients; each share is of general payments naming this product in 2023.
The top 5 of 8 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
The top 5 of 7 states; each share is of general payments naming this product in 2023 where a state was reported.
Records
802 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.